A novel high-throughput neutralization assay for supporting clinical evaluations of human cytomegalovirus vaccines

Vaccine

Volumn 29, Issue 46, 2011, Pages 8350-8356

  Tang, Aimin ^a   Li, Fengsheng ^a   Freed, Daniel C ^a   Finnefrock, Adam C ^a   Casimiro, Danilo R ^a   Wang, Dai ^a   Fu, Tong Ming ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

HCMV vaccines; Human cytomegalovirus; Neutralizing antibodies; Viral neutralization

Indexed keywords

CYTOMEGALOVIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIGEN;

ADULT; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG SCREENING; FEMALE; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN EXPERIMENT; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

ADOLESCENT; ADULT; ANIMALS; CYTOMEGALOVIRUS VACCINES; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MACACA MULATTA; NEUTRALIZATION TESTS; PREGNANCY; YOUNG ADULT;

EID: 80053972903     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.086     Document Type: Article

References (25)

1. Kenneson A., Cannon M.J. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007, 17:253-276.
2. Arvin A.M., Fast P., Myers M., Plotkin S., Rabinovich R. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 2004, 39:233-239.
3. Schleiss M.R., Heineman T.C. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines 2005, 4:381-406.
4. Institute of Medicine, editor. Vaccines for the 21st century: a tool for decision-making. National Academies Press; 2001.
5. Fowler K.B., Stagno S., Pass R.F. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003, 289:1008-1011.
6. Fowler K.B., Stagno S., Pass R.F., Britt W.J., Boll T.J., Alford C.A. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992, 326:663-667.
7. Nigro G., Adler S.P., La Torre R., Best A.M. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005, 353:1350-1362.
8. Pass R.F., Zhang C., Evans A., Simpson T., Andrews W., Huang M.L., et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009, 360:1191-1199.
9. Mocarski ES, Shenk T, Pass RF, editors. Cytomegaloviruses. Lippincott Williams & Wilkins; 2007.
10. Hahn G., Revello M.G., Patrone M., Percivalle E., Campanini G., Sarasini A., et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 2004, 78:10023-10033.
11. Wang D., Shenk T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 2005, 79:10330-10338.
12. Britt W.J. Human cytomegalovirus: propagation, quantification, and storage. Curr Protoc Microbiol 2010, Chapter 14:Unit 14E 3.
13. Gonczol E., Furlini G., Ianacone J., Plotkin S.A. A rapid microneutralization assay for cytomegalovirus. J Virol Methods 1986, 14:37-41.
14. Andreoni M., Faircloth M., Vugler L., Britt W.J. A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J Virol Methods 1989, 23:157-167.
15. Zerbini M., Plazzi M., Musiani M. Rapid neutralization assay for human cytomegalovirus antibody. J Clin Microbiol 1985, 21:969-971.
16. Abai A.M., Smith L.R., Wloch M.K. Novel microneutralization assay for HCMV using automated data collection and analysis. J Immunol Methods 2007, 322:82-93.
17. Wang Z., Mo C., Kemble G., Duke G. Development of an efficient fluorescence-based microneutralization assay using recombinant human cytomegalovirus strains expressing green fluorescent protein. J Virol Methods 2004, 120:207-215.
18. Wong S.K. A 384-well cell-based phospho-ERK assay for dopamine D2 and D3 receptors. Anal Biochem 2004, 333:265-272.
19. Gerna G., Percivalle E., Sarasini A., Baldanti F., Campanini G., Revello M.G. Rescue of human cytomegalovirus strain AD169 tropism for both leukocytes and human endothelial cells. J Gen Virol 2003, 84:1431-1436.
20. Rice G.P., Schrier R.D., Oldstone M.B. Cytomegalovirus infects human lymphocytes and monocytes: virus expression is restricted to immediate-early gene products. Proc Natl Acad Sci USA 1984, 81:6134-6138.
21. Cui X., Meza B.P., Adler S.P., McVoy M.A. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 2008, 26:5760-5766.
22. Schuessler A., Sampaio K.L., Sinzger C. Improvement of a quantitative cell tropism assay for rapid and reliable characterization of human cytomegalovirus mutants. J Virol Methods 2010, 167:218-222.
23. Gerna G., Lilleri D., Fornara C., Comolli G., Lozza L., Campana C., et al. Monitoring of human cytomegalovirus-specific CD4+ and CD8+ T-cell immunity in patients receiving solid organ transplantation. Am J Transplantation 2006, 6:2356-2364.
24. Lilleri D., Fornara C., Furione M., Zavattoni M., Revello M.G., Gerna G. Development of human cytomegalovirus-specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus. J Inf Dis 2007, 195:1062-1070.
25. Griffiths P.D., Stanton A., McCarrell E., Smith C., Osman M., Harber M., et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377:1256-1263.